Answers are grounded in this paper and cite their sources.
Background : Mental disorders are a serious challenge to public health. In recent years, the epidemiological burden of anxiety disorders in a global and European context has increased significantly (WHO 2022). The aim of the study is to measure drug utilization and assess rational drug use in the treatment of patients with anxiety disorders in Bulgaria through quantitative and qualitative indicators at a national level. Materials and methods : The study design is a retrospective, observational, longitudinal study of data from international analytical companies and literature references for the period 2015–2024, using the WHOATC/DDD methodology and descriptive statistical methods. Results and discussion : Epidemiological, health-demographic, and clinical-pharmacological data of the studied population were analyzed. Various qualitative indicators were used—costs of the disease (cost per year), cost per capita per year, monthly cost (cost per month), and cost per treatment day. The studied segment is not reimbursed. The cost per DDD and the cost per prescribed daily dose were calculated. One of the most important indicators—drug utilization, better known in practice as the “top-ten list”—was determined. The top 10 INNs in the different aspects of drug utilization are presented. The results show that the system is not well balanced. Bulgarian doctors are familiar with and apply modern standards, as evidenced by the dominance of SSRIs, but financial dependence distorts their decisions and patients’ options. The growing consumption of pregabalin and the use of lorazepam are symptoms of a system in which the lack of reimbursement leads to market self-regulation, which is not always conducive to rational drug use.
No takes yet. Share an insight, caveat, or question.
Kadiev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: